---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-033196"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2023-09-20T23:59:59+00:00"
generated_at: "2026-06-10T12:20:44.289320+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anebulo reports FY2023 net loss of $11.7M; cash $11.2M; FDA supports Phase 3

## Summary
- Net loss for FY2023 was $11.7M ($0.47 per share) vs $6.8M ($0.29) in FY2022.
- Cash and cash equivalents at June 30, 2023 were $11.2 million.
- Positive FDA Type B meeting supports advancing ANEB-001 to registrational studies; Phase 3 targeting H1 2024.
- Dosing completed in Part C open-label extension of Phase 2 study; data readout expected Q4 2023.
- Operating expenses in FY2023 were $11.8M, up from $6.8M, driven by R&D and G&A increases.

## SEC filing metadata
- accession: 0001493152-23-033196
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2023-09-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/0001493152-23-033196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-033196
- JSON: https://secwatch.observer/filing/0001493152-23-033196.json
- Plain text: https://secwatch.observer/filing/0001493152-23-033196.txt

## Key facts
- Earnings Releases
  Anebulo Pharmaceuticals, Inc. reported three months ended June 30, 2023 results: net income Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share, EPS $(0.10) per share.
  - Period: three months ended June 30, 2023
  - Net income: Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share
  - EPS: $(0.10) per share
  - Result: reported results
  source text: Net loss in the fourth quarter of fiscal 2023 was $2.5 million, or $(0.10) per share, compared with a net loss of $2.3 million, or $(0.10) per share, in the fourth quarter of fiscal 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/0001493152-23-033196-index.htm
- Earnings Releases
  Anebulo Pharmaceuticals, Inc. reported twelve months ended June 30, 2023 results: net income Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share, EPS $(0.47) per share.
  - Period: twelve months ended June 30, 2023
  - Net income: Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share
  - EPS: $(0.47) per share
  - Result: reported results
  source text: Net loss in fiscal year 2023 was $11.7 million, or $(0.47) per share, compared with a net loss of $6.8 million, or $(0.29) per share, in fiscal year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223033196/0001493152-23-033196-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.